The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Share News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Plethora's PSD502 drug has mass market potential

Wed, 17th Oct 2012 15:15

Plethora Solutions is definitely a small cap stock to watch and in an exclusive interview with Sharecast, Daniel Stewart analyst Vadim Alexandre has reiterated the bull case for the biotech tiddler.Plethora Solutions has a drug, PSD502, aimed at treating premature ejaculation, which has passed two phase III trials and is currently awaiting European approval. This approval is expected late in the third quarter or early fourth quarter of 2013. Importantly, it announced at its interims on December 28th that talks "had commenced with multiple parties to identify a commercial partner to bring PDS502 product to market.Alexandre believes the stock is "grossly undervalued" and has placed a price target of 15.7p on it, 214% upside on its current 5p price. Now, as house broker you might perhaps expect him to be keen on the stock but he's positively enthusiastic, while noting that its closing cash balance at the interims was only £0.2m, which means: "We estimate that the company will need to secure further financing."He's confident that the next 12 months will see the transformation of the company, with the signing of a deal probably before EU approval, as any partner would have to factor in a ramp-up period prior to the product's launch. With that deal would come some sorely needed funds.With an estimated 30m European men as potential targets for this treatment it may be a compelling investment case.Alexandre thinks it is: "We believe that PSD502 has the potential to 'go mass market'. Should this transpire, our estimates of the treatment's market potential would be significantly increased. That said, even if the treatment achieves a fraction of this market penetration, Plethora's business would be substantially transformed."For those of a cautious disposition, who like to invest in well-funded companies, it might be worth holding off until any deal is announced. Yet, the fact that billionaire Jim Mellon, a non-executive director of the company, has been funding the company in return for shares, ought to offer some reassurance for those prepared to gamble on this biotech play.CM
More News
12 Mar 2014 09:03

Wednesday broker round-up UPDATE

Ashtead Group: Citi raises target price from 850p to 1075p keeping a buy recommendation. Barratt Developments: Goldman Sachs reduces target price from 527p to 502p and downgrades to neutral. British Land: Jefferies downgrades to hold with a target price of 707p. Brooks Macdonald Group: Canaccord

Read more
11 Mar 2014 14:16

UK MIDDAY BRIEFING: African Barrick Gold Hit By Stake Sale

LONDON (Alliance News) - African Barrick Gold has fallen sharply Tuesday after parent Barrick Gold Corp sold a 10% stake, while Sports Direct International is up after the company's board said it will again try and give Mike Ashley a bigger stake as payment fo

Read more
11 Mar 2014 13:51

CORRECT: UK WINNERS & LOSERS: African Barrick Gold Leads FTSE 250 Fallers

(An item published at 1145 GMT mistated the year-earlier period in the Fenner summary and the revenue figures in the Inchcape summary. The correct version follows:) LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Tues

Read more
11 Mar 2014 11:45

UK WINNERS & LOSERS: African Barrick Gold Leads FTSE 250 Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Tuesday.

-------

FTSE 100 - WINNERS

Sports Direct International, up 2.5%. The sports goods retailer said it

Read more
11 Mar 2014 10:20

Plethora soars on drug development update

Plethora Solutionas saw its value jump by around a third on Tuesday morning after it revealed a meeting with the US Food and Drug Administration (FDA) had resulted in a clear pathway to the successful submission of a new drug application. The application is for PSD 502, a drug used in the treatmen

Read more
11 Mar 2014 09:47

Plethora Solutions Shares Jump 33% As It Moves Ahead With PSD 502

LONDON (Alliance News) - Shares in Plethora Solutions Holdings PLC jumped 33% Tuesday morning after it said it was in negotiations with a number of potential marketing partners for its premature ejaculation treatment PSD 502. The company said following its meeting with the US Food and Drug

Read more
3 Feb 2014 09:20

Plethora Solutions Mulls Dosage Change That Could Raise Profit Potential

LONDON (Alliance News) - Plethora Solutions PLC Monday said it is considering reducing the size of the doses of its premature ejaculation treatment that it eventually brings to market, potentially increasing the profits it can make, as it also said it had a positive initial meeting with US regula

Read more
28 Nov 2013 12:27

CORRECT: AIM IN BRIEF: Herstal Emerges As Favourite To Acquire Manroy

Read more
28 Nov 2013 11:41

Plethora Solutions Slides As CEO Unexpectedly Departs

Read more
28 Nov 2013 08:22

AIM IN BRIEF: Beretta Emerges As Favourite To Acquire Manroy

Read more
22 Nov 2013 12:13

STOCKS NEWS EUROPE-UK small caps up 0.2 pct at mid-session

The FTSE small cap index is up 0.2 percent into mid-session and junior-listed AIM shares gain 0.3 percent, both outperforming a 0.2 percent fall on the blue chips. Shares in AIM-listed investment company Clear Leisure more than double in price to 2.61 pence in heavy volumes after receiving

Read more
22 Nov 2013 09:17

Plethora Solutions Talking With Several Parties About Sales Of Its Treatment

Read more
22 Nov 2013 07:40

AIM IN BRIEF: IMIC Share Placing Raises GBP13.0 Million

Read more
19 Nov 2013 12:28

UK WINNERS & LOSERS: Travel Stocks Take Off; Afren, Lekoil Lifted By Nigeria Find

Read more
19 Nov 2013 10:49

Plethora Gets European Marketing Approval For Ejaculation Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.